When to Use Breast Cancer IndexVideo Categories: PMO Interview with the Innovator Series: Volume 8
Drs. Roy Herbst and David Rimm discuss ways in which the time required to complete biomarker testing can be reduced, from obtaining and processing tissues, performing the testing, evaluating results, and reporting results to the cancer care team.
Alexander Bastian speaks about the need for a sustainable model of pricing as related to cancer treatments and drug development. He talks about indication-based pricing or tumor-based pricing—says that is compelling, but not necessarily possible in the US.